AstraZeneca Annual Report and Form 20-F Information 2011

This section contains further information about the performance of our products within the geographical areas in which our sales and marketing efforts are focused.

For more information regarding our products, see the Therapy Area Review. Details of material legal proceedings can be found in Note 25 to the Financial Statements and details of relevant risks are set out in the Principal risks and uncertainties section.

See the Market definitions table for information about AstraZeneca’s market definitions.

2011 in brief

  • In the US, sales were down 2% to $13,426 million (2010: $13,727 million). The pricing impact from US healthcare reform measures lowered revenue by around 3.3%. Good growth for Crestor, the Seroquel franchise, Symbicort and OnglyzaTM broadly offset the impact of generic competition for Arimidex, Toprol-XL and Merrem, and declines in Nexium.
  • Sales in Western Europe were down 11% to $8,501 million (2010: $9,168 million), due largely to volume erosion on Nexium, Arimidex and Merrem. This was partially offset by volume growth attributable to Crestor, Seroquel XR, Symbicort, Iressa and Faslodex.
  • Established ROW sales were up 4%, driven by continued growth for Symbicort, Crestor, Nexium and Seroquel. In 2011, AstraZeneca became the largest research-based pharmaceutical company in Canada by sales value.
  • Emerging Markets sales increased by 10% to $5,763 million (2010: $5,198 million), with sales growth in China of 15% and Russia of 19%. Sales in Brazil were down as a result of generic competition for Crestor and Seroquel IR.
  • AstraZeneca is the fourth largest pharmaceutical company in the US, with a 6% market share of US prescription pharmaceuticals by sales value and is the sixth largest prescription-based pharmaceutical company in Western Europe, with a 4.4% market share of prescription sales by value.
2011 2010 2009
Sales
$m
Reported
growth
%
CER
growth
%
Sales
$m
Reported
growth
%
CER
growth
%
Sales
$m
US 13,426 (2) (2) 13,727 (7) (7) 14,777
Western Europe 8,501 (7) (11) 9,168 (1) 2 9,252
Canada 1,604 6 1 1,510 26 14 1,203
Japan 3,064 17 6 2,617 11 4 2,367
Other Established ROW 1,233 18 4 1,049 23 6 853
Established ROW 5,901 14 4 5,176 17 7 4,423
Emerging Europe 1,244 7 7 1,165 7 6 1,091
China 1,261 20 15 1,047 29 28 811
Emerging Asia Pacific 968 9 5 890 14 7 780
Other Emerging ROW 2,290 9 12 2,096 26 20 1,670
Emerging Markets 5,763 11 10 5,198 19 16 4,352
Total 33,591 1 (2) 33,269 1 32,804
US

 

Therapy area review

therapy_area_review.jpg

Download centre

download_center.jpg
null null null null null null null null null null null null null null null null null null